Search Within

Yelena Yuriy Janjigian

Formats
  1. Meeting Abstract (219)
  2. Journal Article (157)
  3. Review (11)
  4. Editorial (6)
  5. Book Section (3)
  6. Guidelines (2)
  7. Research Letter (2)
  8. Conference Paper (1)
  9. Correspondence (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (403)
  2. Gastrointestinal Oncology Service (403)
  3. Solid Tumor Oncology Division (403)
  4. Center for Pancreatic Cancer Research (161)
  5. Surgery (149)
  6. Department of Pathology and Laboratory Medicine (137)

More Groups

People
  1. David Ilson (112)
  2. Geoffrey Ku (110)
  3. Laura Tang (84)
  4. David Kelsen (74)
  5. Daniela Molena (65)
  6. Steven Maron (65)

More People

Years
  1. 2025 (23)
  2. 2024 (33)
  3. 2023 (42)
  4. 2022 (37)
  5. 2021 (54)
  6. 2020 (23)

More Years

Publications
  1. Journal of Clinical Oncology (146)
  2. Annals of Oncology (46)
  3. Annals of Surgical Oncology (14)
  4. Annals of Surgery (13)
  5. Clinical Cancer Research (13)
  6. Oncology Research and Treatment (11)

More Publications

Publishers
  1. American Society of Clinical Oncology (152)
  2. Oxford University Press (53)
  3. American Association for Cancer Research (28)
  4. Springer (22)
  5. Elsevier Inc. (19)
  6. Elsevier Science, Inc. (17)

More Publishers

Results (403)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical implications of the cancer genome atlas molecular classification system in esophagogastric cancer
    Journal Article

    Walch, H. S.; Borpatragohain, R.; Jee, J.; Chatila, W.; Fong, C.; Maron, S. B.; Ku, G. Y.; Ilson, D. H.; Janjigian, Y. Y.; Wu, A. J.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Genomic landscape of adenocarcinomas across the gastroesophageal junction moving on from the Siewert classification
    Journal Article

    Nakauchi, M.; Walch, H. S.; Nussenzweig, S.; Carr, R.; Vos, E.; Berger, M. F.; Schultz, N.; Janjigian, Y.; Wu, A.; Tang, L.; more...
    Annals of Surgery (2025)

    Fulltext@MSK | Save
  • Host tissue factors predict immune surveillance and therapeutic outcomes in gastric cancer
    Journal Article

    Abate, M.; Stroobant, E. E.; Fei, T.; Lin, Y. H.; Shimada, S.; Drebin, H.; Chen, E.; Tang, L. H.; Shah, S. P.; Wolchok, J. D.; more...
    Cancer Immunology Research (2025)

    Fulltext@MSK | Save
  • Genomic landscape of late-stage gastric cancer: Analysis from KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 studies
    Journal Article

    Janjigian, Y. Y.; Cecchini, M.; Shitara, K.; Enzinger, P. C.; Wainberg, Z. A.; Chau, I.; Satoh, T.; Lee, J.; Nebozhyn, M.; Loboda, A.; more...
    JCO Precision Oncology (2025)

    Fulltext@MSK | Save
  • Landscape of subsequent therapies in perioperative immunotherapy trials across multiple cancer types
    Journal Article

    Semaan, K.; Nawfal, R.; Nally, E.; Janjigian, Y. Y.; Robert, C.; Peters, S.; Powles, T.; Choueiri, T. K.
    Lancet Oncology (2025)

    Fulltext@MSK | Save
  • A phase II study of agenT-797 (invariant natural killer T-cells), botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) in patients with advanced, refractory gastroesophageal adenocarcinoma
    Meeting Abstract

    Cytryn, S. L.; Maron, S. B.; Janjigian, Y. Y.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • CLARITY-Gastric 01: A randomized phase 3 study of AZD0901, a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC/GEJC)
    Meeting Abstract

    Janjigian, Y. Y.; Shitara, K.; Elimova, E.; Zhang, J.; Chen, M. H.; Smyth, E. C.; Lee, J.; Miao, R.; Liu, S.; Holmblad, M.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Valemetostat and trastuzumab deruxtecan (T-DXd) in previously treated advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric cancer or gastro-esophageal junction (GEJ) adenocarcinoma
    Meeting Abstract

    Shitara, K.; Enzinger, P. C.; Mohapatra, A.; Janjigian, Y. Y.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • KEYMAKER-U06: Phase 1/2 umbrella platform study of TROP2 antibody-drug conjugate sacituzumab tirumotecan plus pembrolizumab plus chemotherapy (substudy 06C) and sacituzumab tirumotecan plus paclitaxel (substudy 06D) in gastroesophageal adenocarcinoma
    Meeting Abstract

    Oh, D. Y.; Xu, J.; Tabernero, J.; Van Cutsem, E.; He, T.; Bhaumik, S.; Bhagia, P.; Janjigian, Y. Y.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Updated results from the trastuzumab deruxtecan (T-DXd) 5.4 mg/kg triplet combination of DESTINY-Gastric03 (DG-03): First-line (1L) T-DXd with fluoropyrimidine (FP) and pembrolizumab in advanced/metastatic HER2-positive (HER2+) esophageal adenocarcinoma, gastric cancer (GC), or gastroesophageal junction adenocarcinoma (GEJA)
    Meeting Abstract

    Janjigian, Y. Y.; Van Laarhoven, H. W. M.; Rha, S. Y.; Kozlov, V.; Oh, D. Y.; Gravina, A.; Rapatoni, L.; Shoji, H.; Hofheinz, R. D.; Chen, L. T.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save